| Date Checked | 2025-12-21 23:38:18 |
|---|
| Graham Number | (PB)145.96 vs (PE)96.99 |
|---|
| Over / Under Value Percentage | 189.59% vs 223.14% |
|---|
| Dividend Yield | 0.00% |
|---|
| Dividend Date | None |
|---|
| Symbol | VRTX |
|---|
| AssetType | Common Stock |
|---|
| Name | Vertex Pharmaceuticals Inc |
|---|
| Description | Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. |
|---|
| CIK | 875320 |
|---|
| Exchange | NASDAQ |
|---|
| Currency | USD |
|---|
| Country | USA |
|---|
| Sector | LIFE SCIENCES |
|---|
| Industry | PHARMACEUTICAL PREPARATIONS |
|---|
| Address | 50 NORTHERN AVENUE, BOSTON, MA, US |
|---|
| FiscalYearEnd | December |
|---|
| LatestQuarter | 2023-12-31 |
|---|
| MarketCapitalization | 107975328000 |
|---|
| EBITDA | 4477000000 |
|---|
| PERatio | 30.12 |
|---|
| PEGRatio | 0.563 |
|---|
| BookValue | 68.22 |
|---|
| DividendPerShare | None |
|---|
| EPS | 13.88 |
|---|
| RevenuePerShareTTM | 38.3 |
|---|
| ProfitMargin | 0.367 |
|---|
| OperatingMarginTTM | 0.38 |
|---|
| ReturnOnAssetsTTM | 0.132 |
|---|
| ReturnOnEquityTTM | 0.23 |
|---|
| RevenueTTM | 9869200000 |
|---|
| GrossProfitTTM | 5323100000 |
|---|
| DilutedEPSTTM | 13.88 |
|---|
| QuarterlyEarningsGrowthYOY | 0.181 |
|---|
| QuarterlyRevenueGrowthYOY | 0.093 |
|---|
| AnalystTargetPrice | 464.98 |
|---|
| AnalystRatingStrongBuy | 8 |
|---|
| AnalystRatingBuy | 13 |
|---|
| AnalystRatingHold | 8 |
|---|
| AnalystRatingSell | 1 |
|---|
| AnalystRatingStrongSell | 1 |
|---|
| TrailingPE | 30.12 |
|---|
| ForwardPE | 25.64 |
|---|
| PriceToSalesRatioTTM | 10.94 |
|---|
| PriceToBookRatio | 6.14 |
|---|
| EVToRevenue | 9.89 |
|---|
| EVToEBITDA | 21.19 |
|---|
| Beta | 0.351 |
|---|
| 52WeekHigh | 448.4 |
|---|
| 52WeekLow | 313.47 |
|---|
| 50DayMovingAverage | 422.69 |
|---|
| 200DayMovingAverage | 378.0 |
|---|
| SharesOutstanding | 258308000 |
|---|
| ExDividendDate | None |
|---|
| dateChecked | 2025-12-21 23:38:18 |
|---|
| fresh | 1 |
|---|